Mr. Gerard Caelles is the Chief Business Officer at SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. Since joining SpliceBio in 2016, he has played a pivotal role in the company's growth from a platform company to a gene therapy-focused company, driving its seed, $57M Series A and $135M

series B financings and forging strategic partnerships with key stakeholders in the biopharmaceutical industry. Beyond corporate and business strategy, he has been instrumental in shaping SpliceBio's pipeline, playing a key role in defining the company's R&D strategy. He is also a co-inventor of several of the company's core technologies.

Gerard has dedicated his career to building biotechnology startups focused on rare diseases. Before SpliceBio, he led business development at Bionure and contributed to the development of BN-201, now OCS-05, a novel drug in Phase 2 trials for a rare neuro-ophthalmology condition called Acute Optic Neuritis.

Gerard holds a degree in Biotechnology from the Universitat Autonoma de Barcelona. A biotechnologist at heart, his life is driven by the ambition to turn cutting-edge science into meaningful therapies for patients.